title: [Recent therapeutic modalities in chronic inflammatory bowel diseases: 4- or 5-aminosalicylic acid?].
abstract: In search of new therapies in IBD, the introduction of 4-aminosalicylic acid (4-ASA) has been proposed based on the longstanding, positive clinical experience in tuberculosis, the expected similar modes of action due to the close structural analogy to 5-aminosalicylic acid (5-ASA), an established therapy in IBD, and its inexpensiveness. To better understand the mechanisms of action of aminosalicylates, the intestinal inflammatory response and to develop new, more effective and cost saving drugs it is important to compare 4-ASA with 5-ASA with respect to their pharmacology, mechanisms of action and clinical efficacy. The inhibition of the upregulation of the initial local immune response, the inhibition of the production of inflammatory mediators, e.g. leukotrienes and the direct scavenging of toxic oxygen metabolites are important common antiinflammatory mechanisms. As the clinical experience with 4-ASA is promising, but still limited, 4-ASA currently cannot yet be recommended outside clinical trials. As the costs of 4-ASA are significantly lower compared to 5-ASA, 4-ASA may replace 5-ASA in the near future provided further trials will confirm the therapeutic and pharmacologic equivalency.
authors.affiliation: Medizinische Klinik I und Krankenhausapotheke des Klinikums Karlsruhe.
authors.forename: H
authors.initials: H
authors.lastname: Allgayer
authors.forename: U
authors.initials: U
authors.lastname: Klotz
authors.forename: P
authors.initials: P
authors.lastname: Böhne
authors.forename: M
authors.initials: M
authors.lastname: Schmidt
authors.forename: W
authors.initials: W
authors.lastname: Kruis
mesh_terms: D010131:Aminosalicylic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D000636:Aminosalicylic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D016718:Arachidonic Acid / Q000378:metabolism; D005609:Free Radicals; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000209:etiology; D015227:Lipid Peroxidation / Q000187:drug effects; D019804:Mesalamine; D017382:Reactive Oxygen Species / Q000378:metabolism
chemical_list: D000636:Aminosalicylic Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005609:Free Radicals; D017382:Reactive Oxygen Species; D016718:Arachidonic Acid; D019804:Mesalamine; D010131:Aminosalicylic Acid
vernacular_title: Neuere Therapieformen bei chronisch-entzündlichen Darmerkrankungen: 4- oder 5-Aminosalicylsäure?